NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SAN DIEGO, March 10, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced its Chief Financial Officer, Wes Brazell, will present an update on the Company's business at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton in Dana Point, CA.
Mr. Brazell’s presentation will be webcast live and archived for at least 90 days on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investors section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB.'
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial and operational performance, opportunities associated with new program offerings, accessing future capital, plans with respect to our marketing strategy and changes in management. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the SEC on November 16, 2015. We do not undertake to update any forward-looking statements except as required by law.
CONTACTS: Investors: Stephen Kilmer (647) 872-4849 [email protected]
